Quantitative cytofluorometric analysis of BV subsets among CD8 T cells of patients
| . | T13/M6 . | T13/M10 . | T17/M9 . | T18/M9 . | T18/M12 . | T19/M9 . | T19/M14 . | T19/M20 . | T20/M6 . | T20/M12* . |
|---|---|---|---|---|---|---|---|---|---|---|
| BV1S1 | ND | ND | 8.55 | 4.03 | 5.11 | 1.29 | 1.76 | 1.41 | 4.30 | 5.62 |
| BV2S1 | 19.00 | 34.00 | 8.47 | 4.41 | 5.24 | 2.16 | 2.30 | 2.48 | 4.11 | 5.32 |
| BV3S1 | ND | ND | 1.65 | 0.38 | 2.24 | 2.25 | 0.00 | 1.02 | 2.28 | 1.54 |
| BV5S1 | ND | ND | 4.43 | 1.79 | 3.42 | 3.67 | 3.80 | 4.07 | 9.18 | 10.40 |
| BV5S2 | ND | ND | 0.60 | 0.49 | 0.48 | 0.20 | 0.42 | ND | 0.81 | 0.98 |
| BV5S3 | ND | ND | 0.85 | 0.49 | 0.70 | 0.25 | 0.57 | ND | 0.25 | 0.26 |
| BV7S1 | ND | ND | 7.16 | 2.04 | 3.62 | 9.22 | 13.28 | 22.51† | 1.10 | 0.96 |
| BV8S1 | ND | ND | 4.59 | 2.04 | 3.29 | 2.60 | 3.14 | 3.84 | 1.49 | 1.73 |
| BV9S1 | ND | ND | 1.23 | 0.80 | 0.90 | 0.77 | 1.14 | ND | 1.06 | 0.90 |
| BV11S1 | ND | ND | 0.81 | 3.37 | 0.53 | 0.50 | 0.45 | ND | 1.00 | 0.57 |
| BV12S1 | ND | ND | 1.92 | 0.66 | 1.05 | 0.25 | 0.60 | ND | 0.57 | 0.59 |
| BV13S1 | ND | ND | 3.03 | 10.98 | 1.83 | 0.80 | 1.21 | ND | 2.01 | 1.82 |
| BV13S6 | ND | ND | 1.86 | 0.77 | 1.16 | 0.45 | 0.61 | ND | 0.71 | 0.50 |
| BV14S1 | ND | ND | 6.4 | 13.05 | 4.9 | 6.77 | 7.26 | 6.53 | 7.50 | 4.63 |
| BV16S1 | ND | ND | 1.35 | 0.21 | 1.15 | 0.29 | 0.52 | ND | 0.60 | 3.95 |
| BV17S1 | ND | ND | 10.89 | 7.84 | 14.94 | 2.29 | 2.19 | 2.31 | 4.91 | 5.09 |
| BV18S1 | ND | ND | 0.30 | 0.39 | 0.6 | 0.10 | 0.26 | ND | 0.13 | 0.24 |
| BV20S1 | ND | ND | 0.76 | 0.77 | 1.5 | ND | 0.35 | ND | 2.23 | 1.40 |
| BV21S3 | ND | ND | 1.52 | 1.22 | 2.5 | 0.51 | 1.45 | ND | 1.33 | 1.24 |
| BV22S1 | ND | ND | 2.72 | 2.55 | 5.37 | 4.00 | 10.47 | 8.96 | 1.72 | 2.53 |
| BV23S1 | ND | ND | 2.15 | 2.01 | 2.38 | 0.32 | 2.07 | ND | 0.91 | 1.33 |
| Total | ND | ND | 71.33 | 60.36 | 62.90 | 38.87 | 53.92 | ND | 48.30 | 51.72 |
| . | T13/M6 . | T13/M10 . | T17/M9 . | T18/M9 . | T18/M12 . | T19/M9 . | T19/M14 . | T19/M20 . | T20/M6 . | T20/M12* . |
|---|---|---|---|---|---|---|---|---|---|---|
| BV1S1 | ND | ND | 8.55 | 4.03 | 5.11 | 1.29 | 1.76 | 1.41 | 4.30 | 5.62 |
| BV2S1 | 19.00 | 34.00 | 8.47 | 4.41 | 5.24 | 2.16 | 2.30 | 2.48 | 4.11 | 5.32 |
| BV3S1 | ND | ND | 1.65 | 0.38 | 2.24 | 2.25 | 0.00 | 1.02 | 2.28 | 1.54 |
| BV5S1 | ND | ND | 4.43 | 1.79 | 3.42 | 3.67 | 3.80 | 4.07 | 9.18 | 10.40 |
| BV5S2 | ND | ND | 0.60 | 0.49 | 0.48 | 0.20 | 0.42 | ND | 0.81 | 0.98 |
| BV5S3 | ND | ND | 0.85 | 0.49 | 0.70 | 0.25 | 0.57 | ND | 0.25 | 0.26 |
| BV7S1 | ND | ND | 7.16 | 2.04 | 3.62 | 9.22 | 13.28 | 22.51† | 1.10 | 0.96 |
| BV8S1 | ND | ND | 4.59 | 2.04 | 3.29 | 2.60 | 3.14 | 3.84 | 1.49 | 1.73 |
| BV9S1 | ND | ND | 1.23 | 0.80 | 0.90 | 0.77 | 1.14 | ND | 1.06 | 0.90 |
| BV11S1 | ND | ND | 0.81 | 3.37 | 0.53 | 0.50 | 0.45 | ND | 1.00 | 0.57 |
| BV12S1 | ND | ND | 1.92 | 0.66 | 1.05 | 0.25 | 0.60 | ND | 0.57 | 0.59 |
| BV13S1 | ND | ND | 3.03 | 10.98 | 1.83 | 0.80 | 1.21 | ND | 2.01 | 1.82 |
| BV13S6 | ND | ND | 1.86 | 0.77 | 1.16 | 0.45 | 0.61 | ND | 0.71 | 0.50 |
| BV14S1 | ND | ND | 6.4 | 13.05 | 4.9 | 6.77 | 7.26 | 6.53 | 7.50 | 4.63 |
| BV16S1 | ND | ND | 1.35 | 0.21 | 1.15 | 0.29 | 0.52 | ND | 0.60 | 3.95 |
| BV17S1 | ND | ND | 10.89 | 7.84 | 14.94 | 2.29 | 2.19 | 2.31 | 4.91 | 5.09 |
| BV18S1 | ND | ND | 0.30 | 0.39 | 0.6 | 0.10 | 0.26 | ND | 0.13 | 0.24 |
| BV20S1 | ND | ND | 0.76 | 0.77 | 1.5 | ND | 0.35 | ND | 2.23 | 1.40 |
| BV21S3 | ND | ND | 1.52 | 1.22 | 2.5 | 0.51 | 1.45 | ND | 1.33 | 1.24 |
| BV22S1 | ND | ND | 2.72 | 2.55 | 5.37 | 4.00 | 10.47 | 8.96 | 1.72 | 2.53 |
| BV23S1 | ND | ND | 2.15 | 2.01 | 2.38 | 0.32 | 2.07 | ND | 0.91 | 1.33 |
| Total | ND | ND | 71.33 | 60.36 | 62.90 | 38.87 | 53.92 | ND | 48.30 | 51.72 |
BV indicates variable region of beta chain; ND, not determined.
Percentage CD3+ CD8+ cells stained by the BV-specific mAbs listed in the first column. For each patient (Tn), after the indicated duration of treatment in months (Mn). Values exceeding the corresponding average control value +3 SD, are shown in boldface.
The BV7 subset was further typed CD45RO−, CD45RA+, CD62L−, CD57+, CD28−.